Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Chief Commercial Officer | February 03, 2020 | February 04, 2020 |
| Cibus, Inc.CLXT · Entity 6658 | Chief Business Officer | June 08, 2021 | June 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date February 03, 2020 · Filed February 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,800 |
Reported balance
After 2020-02-03 transaction · row 1
1 source rowRow 1 · 2020-02-03 · Purchase · Acquired 700 · Balance 3,800 F1: Reflects the purchase of 700 shares of the Issuer's common stock on 2/3/20 at a per share purchase price of $1.72 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.91 · Expires 2030-02-03 | Direct | 121,705 |
Reported balance
After 2020-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-03 · Grant · Acquired 50,000 · Balance 121,705 F2: The option vests in 48 equal installments beginning February 29, 2020 and ending January 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the purchase of 700 shares of the Issuer's common stock on 2/3/20 at a per share purchase price of $1.72 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan.
F2: The option vests in 48 equal installments beginning February 29, 2020 and ending January 31, 2024.
Cibus, Inc.
Report date June 08, 2021 · Filed June 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,101 |
Reported balance
After 2021-06-08 transaction · row 1
1 source rowRow 1 · 2021-06-08 · Grant · Acquired 11,601 · Balance 21,101 F1: Restricted Stock Units vest as to 1/3 of the shares on each of the first three anniversaries of the date of the grant. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.54 · Expires 2031-06-08 | Direct | 16,573 |
Reported balance
After 2021-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-08 · Grant · Acquired 16,573 · Balance 16,573 F2: Option vests as to 1/3 of the shares on each of the first three anniversaries of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units vest as to 1/3 of the shares on each of the first three anniversaries of the date of the grant.
F2: Option vests as to 1/3 of the shares on each of the first three anniversaries of the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2021 Filed Jun 10, 2021 20:53 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 16,573 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001615594-21-000072 · primary_doc.xml · derivative · entry 2 Reiter Sarah · CIK 0001734605 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,573 Underlying: Common Stock · 16,573 shares Expires 2031-06-08 F2 · derivative.exercise_date: Option vests as to 1/3 of the shares on each of the first three anniversaries of the date of the grant. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 20:53 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 11,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001615594-21-000072 · primary_doc.xml · nonDerivative · entry 1 Reiter Sarah · CIK 0001734605 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,101 F1 · shares: Restricted Stock Units vest as to 1/3 of the shares on each of the first three anniversaries of the date of the grant. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001209191-20-006290 · doc4.xml · derivative · entry 2 Reiter Sarah · CIK 0001734605 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,705 Underlying: Common Stock · 50,000 shares Expires 2030-02-03 F2 · derivative.exercise_date: The option vests in 48 equal installments beginning February 29, 2020 and ending January 31, 2024. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 700 | $1.72 | $1,204.00 |
DisclosureSEC source: 0001209191-20-006290 · doc4.xml · nonDerivative · entry 1 Reiter Sarah · CIK 0001734605 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 F1 · shares: Reflects the purchase of 700 shares of the Issuer's common stock on 2/3/20 at a per share purchase price of $1.72 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| December 23, 2019 Filed Dec 23, 2019 21:50 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 900 | $5.95 | $5,355.00 |
DisclosureSEC source: 0001209191-19-061814 · doc4.xml · nonDerivative · entry 1 Reiter Sarah · CIK 0001734605 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 Read SEC document |
| November 19, 2019 Filed Nov 20, 2019 14:00 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $4.52 | $4,520.00 |
DisclosureSEC source: 0001209191-19-057375 · doc4.xml · nonDerivative · entry 1 Reiter Sarah · CIK 0001734605 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Read SEC document |
| September 10, 2019 Filed Sep 10, 2019 22:02 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,200 | $6.48 | $7,776.00 |
DisclosureSEC source: 0001209191-19-049070 · doc4.xml · nonDerivative · entry 1 Reiter Sarah · CIK 0001734605 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Read SEC document |
| June 03, 2019 Filed Jun 7, 2019 20:05 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 23,305 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-19-035510 · doc4.xml · derivative · entry 1 Reiter Sarah · CIK 0001734605 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,705 Underlying: Common Stock · 23,305 shares Expires 2029-06-03 F1 · derivative.exercise_date: The Option vests with respect to 25% of the total securities subject to the option on the first anniversary of the date of award, or June 3, 2020, with the remaining 75% vesting in 36 equal installments beginning June 30, 2020 and ending May 31, 2023, subject to the Participant's continued service. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 23:27 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 38,400 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-18-051841 · doc4.xml · derivative · entry 1 Reiter Sarah · CIK 0001734605 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,400 Underlying: Common Stock · 38,400 shares Expires 2028-09-18 F1 · derivative.exercise_date: The options will vest monthly in equal installments over a period of two years from the date of the grant, subject to the Participant's continued service. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 23:18 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0001209191-18-021166 · doc4.xml · derivative · entry 1 Reiter Sarah · CIK 0001734605 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-19 F1 · derivative.exercise_date: The option vests with respect to 25% of the total securities subject to the option on the first anniversary of the date of award, or March 19, 2019, with the remaining 75% vesting in 36 equal installments beginning March 31, 2019 and ending February 28, 2022, subject to the Participant's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.